HUTCHMED (China) (HCM) Stock Forecast, Price Target & Predictions
HCM Stock Forecast
HUTCHMED (China) stock forecast is as follows: an average price target of $17.50 (represents a 7.36% upside from HCM’s last price of $16.30) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
HCM Price Target
The average price target for HUTCHMED (China) (HCM) is $17.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $17.50 to $17.50. This represents a potential 7.36% upside from HCM's last price of $16.30.
HCM Analyst Ratings
According to 6 Wall Street analysts, HUTCHMED (China)'s rating consensus is 'Buy'. The analyst rating breakdown for HCM stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
HUTCHMED (China) Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Jack Lin | Morgan Stanley | $17.50 | $21.45 | -18.41% | 7.36% |
The latest HUTCHMED (China) stock forecast, released on May 14, 2024 by Jack Lin from Morgan Stanley, set a price target of $17.50, which represents a -18.41% decrease from the stock price at the time of the forecast ($21.45), and a 7.36% increase from HCM last price ($16.30).
HUTCHMED (China) Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $17.50 |
| Last Closing Price | $16.30 | $16.30 | $16.30 |
| Upside/Downside | -100.00% | -100.00% | 7.36% |
In the current month, the average price target of HUTCHMED (China) stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to HUTCHMED (China)'s last price of $16.30. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 23, 2024 | Goldman Sachs | Buy | Buy | Hold |
| May 29, 2024 | HSBC | - | Buy | Initialise |
| May 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Nov 23, 2023 | Deutsche Bank | - | Buy | Upgrade |
| Nov 10, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Mar 02, 2023 | Needham | Buy | Buy | Hold |
| Mar 02, 2023 | Craig-Hallum | Buy | Buy | Hold |
| Aug 09, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
HUTCHMED (China)'s last stock rating was published by Goldman Sachs on Aug 23, 2024. The company gave HCM a "Buy" rating, the same as its previous rate.
HUTCHMED (China) Financial Forecast
HUTCHMED (China) Revenue Forecast
| Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $379.31M | $414.77M | $404.85M | $319.35M | $318.48M | $318.48M | $210.04M | $175.22M | $90.66M | $90.66M | $94.06M | $57.28M | $49.94M | $47.25M | $52.87M | $53.62M | $53.62M | $53.62M |
| High Forecast | $379.31M | $414.77M | $404.85M | $319.35M | $318.48M | $318.48M | $210.04M | $175.22M | $90.66M | $90.66M | $94.06M | $57.28M | $49.94M | $47.25M | $52.87M | $53.62M | $53.62M | $56.79M |
| Low Forecast | $379.31M | $414.77M | $404.85M | $319.35M | $318.48M | $318.48M | $210.04M | $175.22M | $90.66M | $90.66M | $94.06M | $57.28M | $49.94M | $47.25M | $52.87M | $53.62M | $53.62M | $47.39M |
| # Analysts | - | 4 | 5 | - | - | 8 | - | - | - | - | - | - | - | 1 | - | 9 | 9 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HUTCHMED (China)'s average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HCM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
HUTCHMED (China) EBITDA Forecast
| Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 4 | 5 | - | - | 8 | - | - | - | - | - | - | - | 1 | - | 9 | 9 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-250.08M | $-273.46M | $-266.92M | $-210.55M | $-209.97M | $-209.97M | $-138.48M | $-115.52M | $-59.78M | $-59.78M | $-62.01M | $-37.77M | $-32.92M | $-31.15M | $-34.86M | $-35.35M | $-35.35M | $-35.35M |
| High Forecast | $-250.08M | $-273.46M | $-266.92M | $-210.55M | $-209.97M | $-209.97M | $-138.48M | $-115.52M | $-59.78M | $-59.78M | $-62.01M | $-37.77M | $-32.92M | $-31.15M | $-34.86M | $-35.35M | $-35.35M | $-31.25M |
| Low Forecast | $-250.08M | $-273.46M | $-266.92M | $-210.55M | $-209.97M | $-209.97M | $-138.48M | $-115.52M | $-59.78M | $-59.78M | $-62.01M | $-37.77M | $-32.92M | $-31.15M | $-34.86M | $-35.35M | $-35.35M | $-37.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict HCM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than HUTCHMED (China)'s previous annual EBITDA (undefined) of $NaN.
HUTCHMED (China) Net Income Forecast
| Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 4 | 5 | - | - | 8 | - | - | - | - | - | - | - | 1 | - | 9 | 9 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $10.47M | $-170.48M | $-144.90M | $-68.49M | $-95.98M | $-468.81M | $-213.77M | $-178.00M | $-58.99M | $-58.99M | $-89.00M | $-55.31M | $-22.87M | $-28.89M | $-26.12M | $-22.69M | $-22.69M | $-22.69M |
| High Forecast | $10.47M | $-170.48M | $-144.90M | $-68.49M | $-95.98M | $-468.81M | $-213.77M | $-178.00M | $-58.99M | $-58.99M | $-89.00M | $-55.31M | $-22.87M | $-28.89M | $-26.12M | $-22.69M | $-22.69M | $-22.69M |
| Low Forecast | $10.47M | $-170.48M | $-144.90M | $-68.49M | $-95.98M | $-468.81M | $-213.77M | $-178.00M | $-58.99M | $-58.99M | $-89.00M | $-55.31M | $-22.87M | $-28.89M | $-26.12M | $-22.69M | $-22.69M | $-22.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HUTCHMED (China)'s average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HCM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
HUTCHMED (China) SG&A Forecast
| Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 4 | 5 | - | - | 8 | - | - | - | - | - | - | - | 1 | - | 9 | 9 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $103.36M | $113.03M | $110.32M | $87.02M | $86.79M | $86.79M | $57.24M | $47.75M | $24.71M | $24.71M | $25.63M | $15.61M | $13.61M | $12.88M | $14.41M | $14.61M | $14.61M | $14.61M |
| High Forecast | $103.36M | $113.03M | $110.32M | $87.02M | $86.79M | $86.79M | $57.24M | $47.75M | $24.71M | $24.71M | $25.63M | $15.61M | $13.61M | $12.88M | $14.41M | $14.61M | $14.61M | $15.48M |
| Low Forecast | $103.36M | $113.03M | $110.32M | $87.02M | $86.79M | $86.79M | $57.24M | $47.75M | $24.71M | $24.71M | $25.63M | $15.61M | $13.61M | $12.88M | $14.41M | $14.61M | $14.61M | $12.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HUTCHMED (China)'s average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to HCM last annual SG&A of $NaN (undefined).
HUTCHMED (China) EPS Forecast
| Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | 4 | 5 | - | - | 8 | - | - | - | - | - | - | - | 1 | - | 9 | 9 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.06 | $-0.20 | $-0.17 | $-0.39 | $-0.55 | $-0.55 | $-1.23 | $-1.02 | $-0.34 | $-0.34 | $-0.51 | $-0.32 | $-0.13 | $-0.17 | $-0.15 | $-0.13 | $-0.13 | $-0.13 |
| High Forecast | $0.06 | $-0.20 | $-0.17 | $-0.39 | $-0.55 | $-0.55 | $-1.23 | $-1.02 | $-0.34 | $-0.34 | $-0.51 | $-0.32 | $-0.13 | $-0.17 | $-0.15 | $-0.13 | $-0.13 | $-0.13 |
| Low Forecast | $0.06 | $-0.20 | $-0.17 | $-0.39 | $-0.55 | $-0.55 | $-1.23 | $-1.02 | $-0.34 | $-0.34 | $-0.51 | $-0.32 | $-0.13 | $-0.17 | $-0.15 | $-0.13 | $-0.13 | $-0.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, HUTCHMED (China)'s projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HCM previous annual EPS of $NaN (undefined).
HUTCHMED (China) Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.86 | $10.00 | 437.63% | - |
| PCRX | Pacira BioSciences | $14.35 | $43.00 | 199.65% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.48 | $11.67 | 160.49% | Buy |
| ALKS | Alkermes | $27.74 | $35.50 | 27.97% | Buy |
| ITCI | Intra-Cellular Therapies | $75.11 | $94.00 | 25.15% | Buy |
| ANIP | ANI Pharmaceuticals | $60.06 | $67.33 | 12.10% | Buy |
| PBH | Prestige Consumer Healthcare | $73.55 | $82.00 | 11.49% | Buy |
| COLL | Collegium Pharmaceutical | $37.38 | $41.50 | 11.02% | Buy |
| HCM | HUTCHMED (China) | $16.30 | $17.50 | 7.36% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $22.36 | $18.67 | -16.50% | Buy |
HCM Forecast FAQ
Is HUTCHMED (China) a good buy?
Yes, according to 6 Wall Street analysts, HUTCHMED (China) (HCM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of HCM's total ratings.
What is HCM's price target?
HUTCHMED (China) (HCM) average price target is $17.5 with a range of $17.5 to $17.5, implying a 7.36% from its last price of $16.3. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will HUTCHMED (China) stock go up soon?
According to Wall Street analysts' prediction for HCM stock, the company can go up by 7.36% (from the last price of $16.3 to the average price target of $17.5), up by 7.36% based on the highest stock price target, and up by 7.36% based on the lowest stock price target.
Can HUTCHMED (China) stock reach $20?
HCM's average twelve months analyst stock price target of $17.5 does not support the claim that HUTCHMED (China) can reach $20 in the near future.
What are HUTCHMED (China)'s analysts' financial forecasts?
HUTCHMED (China)'s analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $794.4M (high $794.4M, low $794.4M), average EBITDA is $-524M (high $-524M, low $-524M), average net income is $-920M (high $-920M, low $-920M), average SG&A $216.48M (high $216.48M, low $216.48M), and average EPS is $-3.133 (high $-3.133, low $-3.133). HCM's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $1.46B (high $1.46B, low $1.46B), average EBITDA is $-961M (high $-961M, low $-961M), average net income is $-480M (high $-480M, low $-480M), average SG&A $397.16M (high $397.16M, low $397.16M), and average EPS is $-1.312 (high $-1.312, low $-1.312).